What is Kerecis?
Founded in 2009 and headquartered in the Westfjords of Iceland, Kerecis is at the forefront of developing innovative products from fish skin for wound healing and tissue regeneration. Leveraging the unique properties of Icelandic cod skin, the company has created a patented technology that preserves the skin's natural structure, making it ideal for medical applications. Kerecis's offerings aim to address unmet needs in the healthcare market by providing effective and sustainable solutions for complex wounds and tissue damage, positioning itself as a key player in the biomaterials and medical device industry.
How much funding has Kerecis raised?
Kerecis has raised a total of $145M across 6 funding rounds:
Series A
$2M
Series B
$3M
Debt
$3M
Series C
$16M
Debt
$21M
Series D
$100M
Series A (2014): $2M with participation from EHF Capital and New Business Venture Fund
Series B (2016): $3M, investors not publicly disclosed
Debt (2018): $3M, investors not publicly disclosed
Series C (2019): $16M featuring Undisclosed
Debt (2020): $21M backed by Silicon Valley Bank
Series D (2022): $100M with participation from Emerson Collective and Kirkbi
Key Investors in Kerecis
Emerson Collective
Emerson Collective is a company that invests in entrepreneurs and innovators who are driven by purpose and a sense of possibility, focusing on addressing complex challenges in education, economic mobility, immigration, and the environment.
Kirkbi
Kirkbi is a private holding and investment company that maintains majority ownership of the LEGO Group, focusing on sustainable long-term investments and managing a diverse portfolio including real estate and renewable energy.
EHF Capital
EHF Capital specializes in providing investment management services, focusing on alternative investment strategies for institutional investors and high-net-worth individuals.
What's next for Kerecis?
With the recent influx of major strategic investment, Kerecis is poised for accelerated growth and innovation. The company is likely to focus on expanding its product pipeline, scaling manufacturing capabilities, and broadening its market reach, particularly in key international markets. Further research and development into new applications for its proprietary fish-skin technology are also anticipated. This substantial backing from prominent investors signals confidence in Kerecis's business model and its potential to disrupt the wound care and tissue regeneration landscape, paving the way for future commercial success and potential strategic partnerships.
See full Kerecis company page
